{"id":"W2883739562","doi":"10.1016/s2468-1253(18)30233-4","title":"Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study","year":2018,"lang":"en","type":"article","venue":"˜The œLancet. Gastroenterology & hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":156,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Dr. Falk Pharma; Celltrion; Boehringer Ingelheim; Gilead Sciences; Amgen; Pfizer; Genentech; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Crohn's disease; Internal medicine; Placebo; Clinical trial; Gastroenterology; Adverse effect; Clinical endpoint; Severity of illness; Maintenance therapy; Surgery; Disease; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001761941,0.0009766184,0.002138577,0.000219066,0.0002326085,0.0009343997,0.0005014416,0.001084386,0.002375706],"category_scores_gemma":[0.001488933,0.0003994101,0.001880163,0.0003104743,0.0006706614,0.0008070528,0.0003265236,0.002184531,0.0004746128],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005173203,"about_ca_system_score_gemma":0.0006403773,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000776949,"about_ca_topic_score_gemma":0.001598819,"domain_scores_codex":[0.9993333,0.0003392107,0.00005591879,0.00008626488,0.00006456876,0.0001207237],"domain_scores_gemma":[0.998754,0.0004501624,0.000260601,0.0001325085,0.00008901706,0.0003135882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9422321,0.004025186,0.006540807,0.001073365,0.00252766,0.0001709471,0.0001052064,0.0003472251,0.003335654,0.0001320603,0.001288316,0.03822137],"study_design_scores_gemma":[0.8616552,0.09488709,0.03625266,0.0001308007,0.003236673,0.0002437692,0.0001048278,0.0005323588,0.0004496863,0.0002536877,0.002204002,0.00004923488],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844342,0.01133823,0.0002308253,0.0006478838,0.0003416328,0.00042536,0.0009469946,0.00003298976,0.00160197],"genre_scores_gemma":[0.9929122,0.003211582,0.0004183983,0.0007407847,0.000323166,0.0003413362,0.00102529,0.000006957993,0.001020348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002375706,"threshold_uncertainty_score":0.009318173,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01730062530458918,"score_gpt":0.2744220794148416,"score_spread":0.2571214541102524,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}